Abstract: Objective  To investigate the relationship between c-ros oncogene 1（ROS1） fusion gene mutation and epidermal growth factor receptor（EGFR） mutation and clinicopathological characteristics in non-small cell lung cancer（NSCLC）. Methods Real-time fluorescence quantitative PCR（QPCR） was performed to examine gene rearrangement of ROS1 fusion gene in 3487 NSCLC patients of Northwest China from December 2014 to December 2017. EGFR mutation was detected by ARMS method for patients with ROS1 fusion gene mutation. The clinicopathological features of patients with double mutations were analyzed. Results Among the 3487 patients， 54 patients（1.5%） occurred ROS1 fusion gene mutation. ROS1 fusion gene mutation was associated with age， gender， smoking history， pathological types and clinical stage （P＜0.05）. Three patients were identified with EGFR mutation from 54 patients who harboring ROS1 fusion genes mutation, including 2 cases of EGFR19 exon deletion mutation （19-del）， and 1 case of EGFR L858R mutations. The 3 double mutative cases were of ROS1 variant 2 （R2）. Conclusion ROS1 fusion gene mutative rate of NSCLC patients in Northwest China is 1.5％. ROS1 fusion gene and EGFR mutations can coexist in NSCLC.

Key words:

Non-small cell lung cancer （NSCLC）')">"> Non-small cell lung cancer （NSCLC）, ROS1 fusion gene, Epidermal growth factor receptor （EGFR）, Mutation, Clinical features